Recent

% | $
Quotes you view appear here for quick access.

Athenahealth, Inc. (ATHN) Message Board

mghmd 28 posts  |  Last Activity: Jun 26, 2015 11:38 AM Member since: Jan 22, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    The opinion of a hematologist

    by mghmd Jun 26, 2015 10:35 AM
    mghmd mghmd Jun 26, 2015 11:38 AM Flag

    The company released the secondary endpoint ON SCHEDULE- I don't know if they were trying to pump up share price.
    Yes, I can and will recommend this stock, which is priced for failure on primary end point when in fact the chances of success are quite high. Keep in mind that the company picked the group with the best response, secondary AML, in two ph 2 studies. Furthermore, as indicated in the press release, remission rate is highly correlated with PFS and OS data.

  • Despite great advances in several hematologic malignancies such as CML, CLL, multiple myeloma and lymphomas, there has been no significant improvement in AML therapy in over 30 years. CPX-351 holds
    orphan drug status and has fast track designation from the FDA, and the study has been supported by the Leukemia and Lymphoma Society. Even if the OS data in early 2016 fails to be +, I think the drug still stands a good chance of gaining approval based on the improved rate of CR. so far demonstrated. CR is needed to perform bone marrow transplant, which if successful, offers the best chance for a durable remission in AML. The drug could certainly garner a few hundred mil in revenue per year, which would be huge for this company with such a tiny market cap..

    Sentiment: Buy

  • Also keep in mind that Heron has a second CINV drug, HTX-019, in clinical development. The company says HTX-019 could be submitted for approval in the second half of 2016. Heron is also working on a post-surgical pain drug, HTX-011, which is likened to Pacira Pharmaceuticals' (PCRX) commercially successful Exparel. I spoke with one significant investor in Heron who believes HTX-011 is the company's "sleeper hit" pipeline product.

  • Significantly improved response rate and overall survival in 60 with refractory disease or early relapse seems assured based on data from EHA, and the drug almost certainly will be used in off label cases as well.

  • New data on cytogenetics are presented and new format for presentation of vosaroxin data. I think they certainly bolster the case for vosaroxin approval

  • Jus finished watching FRONTLINE on salmonella epidemics in chciken production. Is this still as big an issue. Please enlighten me

  • Food distributor Sysco Corp said on Friday that a record U.S. outbreak of avian flu would limit its chicken and egg supply for nine to 18 months, based on information provided to the company by its suppliers.

    Sysco is the biggest U.S. food distributor, whose clients include restaurants, hotels and hospitals. The company is discussing options with its customers, including creating alternative menu items during the period, a Sysco spokesman said in an email.

    It is too soon to tell whether the supply squeeze will have a material impact on financial results, spokesman Charley Wilson said. Poultry accounted for 10 percent of Sysco's revenue in 2014, according to filings.

    Read MoreNebraska declares state of emergency over bird flu

    The U.S. poultry and egg industry is grappling with the country's biggest outbreak on record of avian influenza, which has proven highly infectious and deadly for poultry. Governors in Nebraska, Wisconsin, Minnesota and Iowa have declared a state of emergency, and the outbreak has shown few signs of waning.

    Earlier this week, Cargill Inc said it has implemented increased biosecurity measures at its facilities receiving liquid egg tankers and shell eggs from impacted states and that it is working with egg suppliers to ensure they are employing measures to prevent spread of the flu.

    Meanwhile, on Thursday, Post Holdings Inc, calling the flu a "force majeure event," said it now estimates that 25 percent of its egg supply has been affected. Sysco is a major customer for Post's Michael Foods business, which sells egg products, according to filings.

    Stifel Nicolaus analyst Christopher Growe expects Post's previous estimate of a $20 million financial impact in 2015 to at least double, according to a research note.

    Growe said that Post's contracts require the company to go to the open market and to third parties to replace the lost supply at high prices. "We believe that by declaring force majeure, the company will be able to either pass higher

  • Reply to

    ASCO Abstract

    by mghmd Apr 21, 2015 12:10 AM
    mghmd mghmd Apr 24, 2015 4:39 PM Flag

    Yes, I think there is an excellent chance that the FDA will approve for elderly AML. In fact, I am optimistic that the filing will get fast track status. There is a compelling need for new Rx.

    I think that the pipeline of early stage drugs is under appreciated.

  • It will be a follow up of the 60 yo patients who underwent bone marrow transplant. I would regard this as a +.

  • There are four titles posted, all on solid malignancies. Not bad

  • Reply to

    SELL NOW -Here's why

    by b_as_u_r Apr 14, 2015 12:50 PM
    mghmd mghmd Apr 20, 2015 3:36 PM Flag

    This stock is a strong recommendation of the medical G news letter. They point out that the current price of the stock has already discounted the walls of Angiomax, and they emphasize the powerful pipeline. There are three other drugs likely to get FDA approval this year.

  • VRTX down 6% today since apparently data did not live up to expectations

  • Reply to

    IMGN/Takeda Deal

    by puppetsock843 Mar 23, 2015 1:57 PM
    mghmd mghmd Mar 23, 2015 3:16 PM Flag

    I suspect it had to do with either low $ offered by Takeda, or conflict with one of the many other collaborators already under SGEN's umbrella

    Sentiment: Buy

  • MEIP dropped 66% this morning after disclosing the failure of its drug, pracinostat in ph2, to help patients with myelodysplastic syndrome in conjunction with azacytidene(Vidaza). CELG is a big player in the MDS area with both Reviled and Vidaza(the latter still has patent exclusivity in EU through 2018, although now generic in US). In addition, CELG also has under development CC-486, an oral version of vidaza, which is felt to be more effective. Pracinostat was felt to be very promising and likely the lead candidate for MDS, and having it knocked out of the box, shifts leadership back to CELG. I would also note that CELG is attacking the most prominent symtom of MDS, anemia, by exercising its collaboration option with XLRN to develop luspaterecpt and sotatercept, the data for which looked most exciting based on data presented at ASH 2014. MDS could easily be 1Bil market for CELG

  • Reply to

    can someone help with with estimates

    by chips_dont_lie Mar 18, 2015 10:54 AM
    mghmd mghmd Mar 18, 2015 5:16 PM Flag

    just completed Palestine, Tx plant and starting new plant, all WITHOUT debt. Patience will win out here. Also a good chance that they will be bought out as the smallest co. in the field.

  • Reply to

    Good news for Valor

    by mghmd Feb 24, 2015 1:13 PM
    mghmd mghmd Mar 12, 2015 10:43 AM Flag

    You are wrong! SNSS hopes to get FDA approval based on approval of a pre-defined sub-group of 60 years old, which was highly statistically significant. The head of FDA Heme/Onc Division, Richard Pazdur, seems much more amenable to approving a sub-group that demonstrates OS, which is the toughest parameter to obtain in a study.

  • That is where the scare originated

  • Stock seems way undervalued by every metric. Unfortunately, my sense is that management is very conservative and unlikely to make a significant special dividend or borrow$$ to initiate a share buy back

  • Reply to

    By Any Metric !

    by youandme1998 Feb 27, 2015 9:56 AM
    mghmd mghmd Mar 5, 2015 11:16 AM Flag

    you provide a KEY piece of information. On what do you base your opinion?

  • In regards to the second question, the authors acknowledge that only 1 of 6 responses in patients with PMBCL is unexpectedly low, but owing to the limited numbers of these patients, they are unable to address this question further. Although accrual of PMBCL patients to a phase 2 trial with brentuximab vedotin may be challenging because of the rarity of this disease and the relatively high response rates with standard front-line regimens, such a study is needed. Patients with PMBCL who relapse are often particularly challenging to salvage because the disease tends to be quite aggressive and chemo-refractory, providing a clinical rationale for novel therapies in this patient population.

    Finally, addressing the third question, the study by Jacobsen et al did not assess cell of origin, myc, or bcl-2 expression in the DLBCL patients. Therefore, it is unclear whether response is associated with a specific DLBCL subtype as is observed with lenalidomide and ibrutinib, where OR is higher in the activated B-cell subtype. However, in a recent study by Hu et al, 461 cases of de novo DLBCL (PMBCL was excluded) were assessed for CD30 expression, and 14% were found to have CD30 expression of at least 20%.9 Of these 65 cases, 38, 26, and 1 were germinal-center, activated B cell, or unclassifiable, respectively, by gene expression profiling. None of the CD30+ cases had a detectable myc translocation by fluorescence in situ hybridization, although 38, 26, and 15 patients were found to have myc, bcl-2, or both myc and bcl-2 overexpression by IHC analysis. Moreover, CD30+ patients had a superior overall survival and progression-free survival, with 5-year overall survival and progression-free survival of 79% and 73%, respectively, in the CD30+ group compared with 59% and 57% for the CD30– cases. The favorable outcome of the CD30+ patients was observed regardless of cell of origin. The studies by Hu et al and others demonstrate that we still have a lot to learn about how best to use the

ATHN
114.26-0.12(-0.10%)Jul 2 4:00 PMEDT